prioriti review week decemb
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
ironwood allergan agre patent settlement gener linzess agreement allow market gener
version linzess prior expir patent pend fda approv ith sale gener linzess mcg mcg
start februari linzess mcg start august
ironwood appoint azn exec ceo current ceo join spin-off ironw ood founder current ceo peter hecht set
head spin-off focus solubl guanyl cyclas stimul take ironw ood
mark mallon ho spent last year astrazeneca recent execut vice presid global product portfolio
bristol sprycel approv pediatr philadelphia chromosome-posit acut lymphoblast leukemia
combin chemo approv grant follow ing fda prioriti review base data phase studi
 hich show ed event-fre surviv rate three year
teva settl disput gener version cinacalcet agreement specifi teva ill ceas sell product
mid-year sooner depend certain circumst hen licens date occur part settlement teva ill pay
undisclos amount continu pursu claim remain gener compani hich settl
announc manag chang ahead viaskin peanut bla resubmiss chief scientif offic dr hugh
sampson ill also assum role chief medic offic board member juli oneil formerli evp global oper alexion ill
direct product develop overse resubmiss viaskin peanut bla addit alan kerr svp head
global regulatori affair ill report directli ceo
merck keytruda approv five new indic japan three approv ere expand use non-smal cell
lung cancer nsclc combo ith pemetrexed/chemo advanc nsclc combo ith carboplatin paclitaxel nab-
paclitaxel advanc nsclc monotherapi advanc nsclc keytruda also approv
adjuv monotherapi melanoma monotherapi advanc msi-h solid tumor progress follow ing chemo
enrol first patient phase studi extend interv dose tysabri multipl sclerosi studi ill
assess efficaci safeti toler everi eek dose compar current approv eek dose regimen studi
 ill enrol approxim patient last tw year primari endpoint number new new ly enlarg
hyperintens lesion eek studi intend determin hether less frequent dose reduc risk progress
vertex arbor biotechnolog collabor gene edit therapi collabor ill focu discoveri novel
protein advanc develop gene-edit therapi cystic fibrosi four diseas determin vertex ill
make up-front cash payment invest arbor convert note arbor ill elig mileston royalti payment futur
vertex crispr receiv fast track design sickl cell diseas compani announc fda accept
ind octob enrol phase trial on-going separ trial beta-thalassemia
on-going europ
announc collabor develop treatment neurolog condit collabor
 ill allow access protein degrad platform research potenti target develop product candid
 ill pay up-front potenti mileston plu royalti ill record expens relat
transact
skyhawk therapeut agre collabor develop small molecul rna splice modifi neurolog
condit ill make up-front payment skyhaw ell potenti futur mileston royalti turn
 ill receiv option licens therapi result collabor up-front payment ill alloc betw een futur
research servic expens
astella announc posit data xtandi phase arch trial metastat hormone-sensit prostat cancer
xtandi combin ith androgen depriv therapi met primari endpoint significantli improv radiograph
progression-fre surviv rpf compar ith alon astella manag plan discuss data ith regul support
expand indic xtandi
tizona therapeut form cancer immunotherapi collabor collabor seek develop commerci
therapi target term agreement tizona set receiv up-front ith
also make addit equiti invest phase studi ill lead tizona exclus option continu
develop ith tizona elig receiv develop commerci mileston tier royalti
proprietari research past week
initi overw eight pt
 biopharmaceut compani profil focu
 biopharmaceut hat expect eek sf
corp dear manag board
coverag bmy/celg deal
bmy/celg initi thought bristol celgen
bmy/celg addit thought bristol celgen deal
bmy/celg top question bmy/celg deal
bmy/celg forma financi outlook bmy/celg deal includ work pro forma model
client ask
investor ask follow ing topic phone call email in-person market meet
takeaway bristol/celgen deal ith increas concern opdivo grow th trajectori look
beyond expect investor view bristol propos acquisit celgen neg first glanc hile accret
first full year long-term year cash flow gener posit biggest concern like dilut
deal strateg hat announc impli bristol posit across i/o space admittedli current
commerci outlook seem rel posit evidenc guidanc rais resili opdivo sale strong
non-gaap ep outlook vs consensu anticip share perform ill increasingli tie
grow ing uncertainti broader posit i/o beyond nsclc rcc market said think deal
make strateg sens given good commerci pipelin synergi bristol mostli contribut solid tumor valu celgen contribut
liquid tumor valu alreadi inflamm immunolog pleas see section coverag bmy/celg deal
outlook space head tough year biopharma space mark high
volatil smid cap biotech underw helm perform overallw ith major pharma prove rel safe drg
index nbi index drug approv trend capit market environ ere quit favor
 hich fuel innov sector continu year said expect drug price debate/overhang
 hich creat volatil sector persist throughout henc ed character sector backdrop mix ith
unusu neg sentiment start year root low er expect sector grow th revenu y/i earn
reflect low er multipl larg cap biopharma versu though cant argu uptick
 activ year never seem happen think modest expect neg sentiment today set
group ell modest re-rat biopharmaceut global biopharma outlook
expect next week confer san francisco healthcar confer season kick next eek
san francisco anticip much commentari focu overal expect look ahead given hat ed
character tough end nbi drg broadli speak think gener tone ill larg
conserv larg cap biopharma uninspir low grow th expect though could bullish smid cap
given pace innov pois acceler year view modest expect neg sentiment
head year set group ell modest re-rat maintain posit outlook sector hile
 anticip major data disclosur confer could provid ith increment updat numer
alexion ultomiri vertex cf franchis biopharmaceut hat expect eek sf
watch week ahead
clinic trial read-out regulatori event expect near-term
phase data expect near term
phase data tnbc expect near term
even romosozumab fda advisori committe meet bla submiss
american societi cell biolog ascb annual meet san diego ca decemb
let us know question comment geoff greg jason olivia scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
materi conflict barclay bank plc and/or affili serv financi advisor merck co nyse relat
announc definit purchas agreement hich merck co nyse ill acquir antelliq group
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
